smartdyelivery

  

est. 2014

Our Vision

" Magical spheres " for the therapy of diseases

Our Vision

„We must learn to create magical spheres that ... only hit the pathogens.”

Paul Ehrlich 1854-1915

With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.

NEWS

October 14, 2020

SUCCESSFUL MULTI-MILLION FINANCING ROUND: SmartDyeLivery is pleased to announce the successful completion of its most recent financing round. In addition to bm-t beteiligungsmanagement thüringen gmbh (bm|t), which increased its lead investment, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT), a group of business angels was also convinced. The investment will be used to finance important development steps for the specific therapy of septic liver failure - up to the first application in humans. Read the complete press release here.

October 08, 2020

JOINT PUBLICATION WITH RESEARCHERS FROM THE UNIVERSITY OF JENA: The close cooperation with scientists from the Institute of Organic Chemistry and Macromolecular Chemistry (IOMC), work continued on the jointly developed method for the quantitative investigation of physicochemical properties of nanoparticles, including in human blood serum. The experimentally developed methods will in future allow comprehensive quality assurance in nanomedical applications. The results were published in a joint high-ranking publication in the scientific journal Nanoscale.

September 29, 2020

JOINT PUBLICATION WITH BETEILIGUNGSMANAGEMENT THÜRINGEN GMBH (bm|t): The article »Gezielter Wirkstofftransport – eine Herausforderung« by SmartDyeLivery GmbH and bm-t beteiligungsmanagement thüringen GmbH was published in the e-magazine Plattform Life Sciences - 3/2020 »Biotechnology«. The approach of »packaging« active pharmaceutical ingredients in nanotransporters is expected to play an increasing role in personalized medicine in the future. Read the complete article here.

DEVELOPMENT OF NEW THERAPY OPTIONS

In a first field of application we focus on the targeted transport of active substances in liver cells. We are thus creating a therapeutic option for the treatment of patients with septic cholestasis with the aim of reducing the extremely high mortality rate caused by this complication.

CONTACT

Email

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Botzstraße 5 | 07743 Jena Germany

 

Visitor Adress:

Philosophenweg 7a | 07743 Jena Germany

Funding

             INVEST Logo URL rote URL RZ quadr2
         
 
 
TAB

 

zim 4c klein

Copyright © 2015 - 2018 redcat DESIGNGROUP